A phase III open uncontrolled study of denileukin diftitox in 71 patients with stage IB-IVA CTCL has shown an OR rate of 30%, with 10% showing a complete clinical response.67 Only CTCL cases with biopsies showing >20% CD25+ (IL-2R) lymphocytes were enrolled. Median duration of response was 6-9 months. No difference in response rates or duration of response was noted between 9 and 18 micrograms/kg/day. The development of anti-denileukin diftitox antibodies apparently did not affect response rates.
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.